Novo Nordisk A/S - aktietilbagekøbsprogram

June 14, 2011 05:48 ET | Source: Novo Nordisk A/S Novo Nordisk A/S

For release content, please refer to the attachment.

Attachments

Selskabsmeddelelse nr. 37 2011

Selskabsmeddelelse nr. 37 2011...

Recommended Reading

February 02, 2026 10:43 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial

CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial.
Read More
January 31, 2026 02:00 ET | Source: Novo Nordisk A/S

New employee representative on the Board of Directors of Novo Nordisk A/S

Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S.
Read More